SCF-ECCA-TOX-FIH-CTD-0001
First-in-Human (FIH) Clinical Trial Design
Toxic Encephalopathy
SCF Multi-Omics Neuroimmune Connectomic Reconstruction Platform
Adaptive Biomarker-Guided Precision Acupuncture Clinical Administration Protocol
I. TRIAL OVERVIEW
Study Title
A First-in-Human Adaptive Biomarker-Guided Precision Acupuncture Study for Toxic Encephalopathy Utilizing the SCF Encephalopathy Connectomic Collapse Atlas (ECCA-TOX).
Study Phase
Phase 0/Ia
Trial Design
Prospective
Adaptive
Biomarker-guided
Open-label
Dose-escalation neuromodulation study
Safety and feasibility primary objective
Study Duration
12 weeks
Screening
2 weeks
Active Treatment
8 weeks
Follow-up
2 weeks
II. PRIMARY OBJECTIVES
Safety
Evaluate:
- Serious adverse events (SAEs)
- Neurological deterioration
- Hemodynamic instability
- Syncope
- Seizure occurrence
- Cognitive worsening
Feasibility
Determine:
- Treatment adherence
- Protocol compliance
- Biomarker collection feasibility
- Real-time monitoring capability
III. SECONDARY OBJECTIVES
Evaluate:
- Connectomic restoration
- Neuroimmune normalization
- Autonomic stabilization
- Cognitive recovery
- Functional improvement
- Biomarker responsiveness
IV. TARGET POPULATION
Eligible Toxic Encephalopathy Types
Industrial Toxicity
- Heavy metal encephalopathy
- Solvent toxicity
- Pesticide toxicity
Drug-Induced Toxicity
- Chemotherapy-associated encephalopathy
- Medication-induced encephalopathy
Environmental Toxicity
- Carbon monoxide
- Mold-associated neurotoxicity
- Airborne toxicant exposure
Mixed Toxic-Metabolic Encephalopathy
V. INCLUSION CRITERIA
Age:
18–75
Confirmed toxic encephalopathy diagnosis
MoCA:
10–28
Stable medical treatment
≥14 days
SCF Toxic Connectomic Score:
20–80
Ability to complete monitoring
VI. EXCLUSION CRITERIA
Acute stroke
Active CNS infection
Uncontrolled epilepsy
Brain tumor
Severe psychiatric instability
Mechanical ventilation
Hemodynamic instability
Pregnancy
VII. SCF TOXIC ENCEPHALOPATHY BIOMARKER PANEL
Core Real-Time Monitoring Panel
Neuroaxonal Injury
Biomarker | Assay | Frequency |
NfL | Simoa | Weekly |
UCH-L1 | ELISA | Weekly |
NSE | CLIA | Weekly |
Neuroglial Injury
Biomarker | Assay | Frequency |
GFAP | Simoa | Weekly |
S100B | Immunoassay | Weekly |
YKL-40 | ELISA | Biweekly |
Neuroimmune Activation
Biomarker | Assay | Frequency |
IL-6 | Multiplex | Weekly |
TNF-α | Multiplex | Weekly |
IL-1β | Multiplex | Weekly |
HMGB1 | ELISA | Weekly |
Toxic Exposure Burden
Biomarker | Assay |
Blood Heavy Metals | ICP-MS |
Urinary Heavy Metals | ICP-MS |
VOC Panel | GC-MS |
Organophosphate Metabolites | LC-MS/MS |
Bioenergetic Function
Biomarker | Assay |
Lactate | Chemistry |
Pyruvate | LC-MS/MS |
Lactate/Pyruvate Ratio | LC-MS/MS |
cf-mtDNA | qPCR |
Connectomic Function
Biomarker | Assay |
qEEG Connectivity | Weekly |
EEG Delta Excess | Weekly |
HRV SDNN | Daily |
HRV RMSSD | Daily |
VIII. ACUPUNCTURE ADMINISTRATION PROTOCOL
Cohort A
Low Intensity
Frequency
2 sessions/week
Duration
20 minutes
Points
GV20
GV24
PC6
ST36
HT7
Cohort B
Moderate Intensity
Frequency
3 sessions/week
Duration
30 minutes
Additional Points
LI11
LI4
SP6
GB20
Cohort C
High Intensity
Frequency
5 sessions/week
Duration
40 minutes
Additional Points
Sishencong
CV17
LV3
KI3
Auricular Shenmen
IX. REAL-TIME ESCALATION RULES
Escalation Criteria
Must meet ALL:
Neuroinflammation
IL-6 decrease
≥20%
AND
TNF-α decrease
≥15%
Connectomics
qEEG Connectivity improvement
≥10%
Neuroaxonal Injury
NfL stable or decreasing
Autonomics
HRV SDNN increase
≥10%
Clinical
MoCA improvement
≥2 points
Escalation Action
Advance to next intensity cohort
after 2 consecutive weeks
meeting criteria
X. DE-ESCALATION RULES
Immediate De-Escalation
If ANY occur:
NfL increase
25%
GFAP increase
25%
IL-6 increase
50%
EEG deterioration
20%
New seizure
Any occurrence
Orthostatic instability
SBP drop
20 mmHg
MoCA decline
≥3 points
Action
Return to prior cohort
Repeat biomarker assessment
Within 48 hours
XI. STOPPING RULES
Immediate Trial Suspension
Any:
- Status epilepticus
- ICU admission
- Acute encephalopathy worsening
- Severe cardiovascular instability
- Unexpected serious adverse event
Subject Withdrawal
If:
NfL doubles from baseline
OR
GFAP doubles from baseline
OR
SCF Toxic Connectomic Score worsens >30%
XII. PRIMARY ENDPOINTS
Safety Endpoints
- SAE incidence
- Neurological worsening
- Seizure frequency
- Cognitive decline
Biomarker Safety Endpoints
- NfL stability
- GFAP stability
- Cytokine stability
XIII. SECONDARY ENDPOINTS
Connectomic Restoration
qEEG Connectivity
rs-fMRI Connectivity
DTI FA
Cognitive Recovery
MoCA
Trail Making Test B
Digit Symbol Test
Autonomic Recovery
HRV
COMPASS-31
Toxic Load Reduction
Heavy metal burden
VOC burden
Toxic metabolite burden
XIV. COMPOSITE SCF TOXIC ENCEPHALOPATHY RESPONSE SCORE
Domain | Weight |
Neuroaxonal Injury | 20% |
Neuroglial Injury | 15% |
Neuroimmune Activity | 15% |
Toxic Burden | 15% |
Bioenergetics | 10% |
Connectomics | 15% |
Autonomics | 5% |
Cognition | 5% |
Interpretation
Score Change | Response |
>30% Improvement | Major Response |
15–30% Improvement | Moderate Response |
5–15% Improvement | Minor Response |
±5% | Stable |
>10% Worsening | Progression |
XV. TRANSLATIONAL DECISION GATES
Go
- No SAE signal
- Biomarker improvement
- Connectomic improvement
Proceed to Phase Ib
Conditional Go
- Safety acceptable
- Biomarkers mixed
Protocol optimization required
No-Go
- Safety signal
- Biomarker worsening
- Connectomic deterioration
Terminate development
NEXT CLINICAL ADMINISTRATION PROTOCOL
SCF-ECCA-HEP-FIH-CTD-0002
Hepatic Encephalopathy FIH Clinical Trial Design
MASTER REGISTRY INDEX
- SCF-ECCA-TOX-FIH-CTD-0001 — Toxic Encephalopathy FIH Clinical Trial Design
- SCF-ECCA-TOX-BIO-0011 — Toxic Encephalopathy Biomarker Panel
- SCF-ECCA-TOX-ACU-0011 — Toxic Encephalopathy Acupoint Neuro-Circuit Atlas
- SCF-ECCA-0001 — Encephalopathy Connectomic Collapse Atlas
- SCF-CLINDEV-0001 — SCF Clinical Development Framework
- SCF-BIOMARKER-ENDPOINTS-0001 — SCF Biomarker Endpoint Validation Framework
- SCF-ACU-NEURO-ATLAS-0001 — SCF Neural Mapping Schema